![]() |
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(1):e81-e83. Published online 2024 Oct 7 DOI: https://doi.org/10.3350/cmh.2024.0829
|
Citations to this article as recorded by
Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
Hiroaki Kanzaki, Yujin Hoshida
Clinical and Molecular Hepatology.2025; 31(1): e121. CrossRef
|